SCHEMBL24257749

SCHEMBL24257749

Nc1ccc(-n2cc(Br)cn2)c(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.44
KDM4E B2RXH2 2/20 0.44
RAD52 P43351 1/20 0.44
ALDH1A1 P00352 7/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.41
GAA P10253 2/20 0.41
CYP3A4 P08684 4/20 0.40
HTT P42858 1/20 0.40
NFKB1 P19838 1/20 0.40
PMP22 Q01453 1/20 0.40
PRKCI P41743 1/20 0.38
TSHR P16473 3/20 0.38
HSD17B10 Q99714 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257824 0.83 NOTUM (0.45) MAPTALDH1A1POLBSMN1; SMN2GAA
SCHEMBL11486172 0.82 BCHE (0.43) KDM4EALDH1A1SMN1; SMN2HTTPRKCI
SCHEMBL18153097 0.82 ALDH1A1 (0.45) MAPTKDM4ERAD52ALDH1A1POLB
SCHEMBL11492392 0.78 TSHR (0.49) KDM4EALDH1A1GAAHTTPRKCI
SCHEMBL25432273 0.78 MAPT (0.44) MAPTKDM4ERAD52ALDH1A1POLB
SCHEMBL20319504 0.77 ALDH1A1 (0.41) MAPTKDM4ERAD52ALDH1A1POLB
SCHEMBL26260329 0.75 MAPT (0.48) MAPTALDH1A1SMN1; SMN2GAAHSD17B10
SCHEMBL11496039 0.75 TSHR (0.43) KDM4EALDH1A1POLBGAAHTT
SCHEMBL11486847 0.74 TSHR (0.45) KDM4EALDH1A1PRKCITSHRHSD17B10
SCHEMBL11496178 0.73 CHRM1 (0.44) PRKCIKMT2APLAUELANEMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 MAPT 3325/4885KDM4E 175/4885RAD52 4639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.